Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models.
- Resource Type
- Article
- Authors
- Veeraraghavan, Jamunarani; Gutierrez, Carolina; Sethunath, Vidyalakshmi; Mehravaran, Sepideh; Giuliano, Mario; Shea, Martin J.; Mitchell, Tamika; Wang, Tao; Nanda, Sarmistha; Pereira, Resel; Davis, Robert; Goutsouliak, Kristina; Qin, Lanfang; De Angelis, Carmine; Diala, Irmina; Lalani, Alshad S.; Nagi, Chandandeep; Hilsenbeck, Susan G.; Rimawi, Mothaffar F.; Osborne, C. Kent
- Source
- NPJ Breast Cancer; 5/27/2021, Vol. 7 Issue 1, p1-11, 11p
- Subject
- Language
- ISSN
- 23744677